FDA Approves Oral Semaglutide for Cardiovascular Risk Reduction in Type 2 Diabetes
- 23 October 2025
- 1 week ago
EMA Committee approves update to Novo Nordisk Rybelsus label to reflect cardiovascular benefits
- 18 September 2025
- 1 month ago
Novo Nordisk Gets CDSCO Panel Nod for Rybelsus Label Update, Aligned with EMA
- 10 September 2025
- 1 month ago
Recent News
Nanotechnology Reverses Alzheimer's Symptoms in Mi...
- 03 November, 2025
Gum disease could silently cause serious brain dam...
- 03 November, 2025
Can Early-Day Fasting Significantly Boost Metaboli...
- 03 November, 2025
Delhi HC bars doctor from running medical centre d...
- 03 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.



